CSIMarket
 
Sellas Life Sciences Group Inc   (SLS)
 

Breaking down fourth quarter of 2022 numbers, the Major Pharmaceutical Preparations company's had devastating revenue slide

SLS delivered fourth quarter of 2022 operating loss of $-9.446 million


Published Mar 21 2023
CSIMarket Team / CSIMarket.com


Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_CommonsFor the fiscal time-frame ending December 31 2022 SLS lost money of $-0.36 per share compare to $-0.41 a year ago and grew deficit from $-0.34 per share from the preceding financial reporting period.

The revenue fell sharply by -92.662 % to $0.34 million from $4.67 million in the comparable financial reporting period a year ago and sequentially from $0.00 million.




For the fiscal time-frame ending December 31 2022 Sellas Life Sciences Group Inc realized net deficit of $-9.121 million, bigger than $-6.598 million a year ago.

the Major Pharmaceutical Preparations company announced deficit of $-41.30 million and revenue of $1.33 million in the financial year 2022.

Net deficit per share has widen to $-2.13 from $-1.34 in the preceding financial year, while by -88.86 % from $11.95 million a year ago.

Sellas Life Sciences Group Inc is expected to report next financial earnings on May 11, 2023.



Sellas Life Sciences Group Inc's Effective Tax Rate

Sellas Life Sciences Group Inc's Operating Margin



Other SLS's news

SELLAS Boosts AML Treatment with Promising Phase 2a Data and FDA Fast Track Designation for SLS009

SELLAS Life Sciences Group Raises $20 Million to Spearhead Cancer Research and Development Efforts, Paving the Way for Innovative Therapies

SELLAS Life Sciences Group Secures $20 Million Investment Through Registered Direct Offering and Private Placement

Sellas Life Sciences Group Focuses on Clinical Advancements Amid Executive Leadership Reorganization

SELLAS Life Sciences Presents Exciting SLS009 Data for Acute Myeloid Leukemia Treatment at ESH Conference

Understanding the Mechanisms of Action of SLS009: A Highly Selective CDK9 Inhibitor for Hematologic Malignancies

SLS009: A Potential Breakthrough for Relapsed/Refractory AML Treatment, Supported by Encouraging Phase 2a Study Results.

SELLAS Life Sciences Group, Inc. Announces Public Offering: An Opportunity for Shareholders

SELLAS Life Sciences: Forging New Horizons in Oncology - Corporate Updates and Key Milestones Explored

Revolutionary Immunotherapy Combo Uplifts Survival Prospects for Advanced Malignant Pleural Mesothelioma Patients

Sellas Life Sciences Group Inc Faces Operating Deficit, But Investors Remain Optimistic for Future Growth

Sellas Life Sciences Group Inc. Experiences Eye-Popping $-9.05 Million Operating Shortfall in Q2 2023

Sellas Life Sciences Group Inc Shows Improvement in 2023 First Quarter Results, But Concerns Remain

Breaking down fourth quarter of 2022 numbers, the Major Pharmaceutical Preparations company*s had devastating revenue slide

announced operating loss of $-7.146 millions, in the most recent fiscal period


The Diminishing Returns have expanded more at the amid the financial period closing March 31 2022

Breathtaking data, by the Major Pharmaceutical Preparations company over the most recent fiscal period



Other SLS's news

SELLAS Boosts AML Treatment with Promising Phase 2a Data and FDA Fast Track Designation for SLS009

SELLAS Life Sciences Group Raises $20 Million to Spearhead Cancer Research and Development Efforts, Paving the Way for Innovative Therapies

SELLAS Life Sciences Group Secures $20 Million Investment Through Registered Direct Offering and Private Placement

Sellas Life Sciences Group Focuses on Clinical Advancements Amid Executive Leadership Reorganization

SELLAS Life Sciences Presents Exciting SLS009 Data for Acute Myeloid Leukemia Treatment at ESH Conference

Understanding the Mechanisms of Action of SLS009: A Highly Selective CDK9 Inhibitor for Hematologic Malignancies

SLS009: A Potential Breakthrough for Relapsed/Refractory AML Treatment, Supported by Encouraging Phase 2a Study Results.

SELLAS Life Sciences Group, Inc. Announces Public Offering: An Opportunity for Shareholders

SELLAS Life Sciences: Forging New Horizons in Oncology - Corporate Updates and Key Milestones Explored

Revolutionary Immunotherapy Combo Uplifts Survival Prospects for Advanced Malignant Pleural Mesothelioma Patients

Sellas Life Sciences Group Inc Faces Operating Deficit, But Investors Remain Optimistic for Future Growth

Sellas Life Sciences Group Inc. Experiences Eye-Popping $-9.05 Million Operating Shortfall in Q2 2023

Sellas Life Sciences Group Inc Shows Improvement in 2023 First Quarter Results, But Concerns Remain

Breaking down fourth quarter of 2022 numbers, the Major Pharmaceutical Preparations company*s had devastating revenue slide

announced operating loss of $-7.146 millions, in the most recent fiscal period


The Diminishing Returns have expanded more at the amid the financial period closing March 31 2022

Breathtaking data, by the Major Pharmaceutical Preparations company over the most recent fiscal period



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com